GlaxoSmithKline plc (GSK) today announced results from the 'LABA' (long acting beta 2-agonist) safety study, AUSTRI(SAS115359). The study compared Advair ® Diskus ®, a combination of the LABA, ...

GlaxoSmithKline’s Andrew Witty has spent his entire CEO stint fending off concerns about the arrival of generic Advair. But on his final quarterly conference call as helmsman, he finally laid out just ...

Signage for GlaxoSmithKline is seen on it's offices in London, Britain, March 30, 2016. REUTERS/Toby Melville/File Photo By Ben Hirschler LONDON (Reuters) - GlaxoSmithKline is likely to escape generic ...

Lannett has entered into an exclusive U.S. distribution agreement for Respirent’s generic Advair Diskus (fluticasone propionate – salmeterol xinafoate powder inhaler), which is still pending approval ...

Lannett has submitted an ANDA to the Food and Drug Administration for its strategic partner, Respirant's fluticasone propionate and salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg) ...

Sharon Bassett tries to stretch a month’s supply of GlaxoSmithKline Plc’s Advair over 60 days to save money on the asthma treatment because the U.S. lacks a cheaper generic version. An alternative ...

LONDON, Sept 22 (Reuters) - GlaxoSmithKline gave a promising glimpse on Wednesday of a planned once-daily successor to its blockbuster lung treatment Advair, with results from a small study showing it ...

LONDON (Reuters) - GlaxoSmithKline (GSK.L) is putting more marketing muscle behind its new lung drugs and is looking for a sales boost as top respiratory experts gather to analyse clinical trials data ...

GlaxoSmithKline is shifting its sales strategy for therapy Advair to stress increasing a treatment for chronic obstructive pulmonary disease (COPD), a new report states.Advair, a long-acting beta2 ...

Novartis’ triple combination asthma candidate QVM149 has beaten GlaxoSmithKline’s Advair in a phase 2 trial. The study linked QVM149 to statistically significant improvements in lung function, leading ...

GlaxoSmithKline is shifting its sales force strategy for therapy Advair to stress treatment for chronic obstructive pulmonary disease (COPD), a new report stated. Advair, a long-acting beta2 agonist ...

LONDON (Reuters) - GlaxoSmithKline is likely to escape generic competition to its blockbuster lung drug Advair in the United States this year, after a second application for a cut-price equivalent ...